1Johnson JR, Berggren T, Conway AJ. Activity of a nitrofurazone matrix urinary catheter against catheter associated uropathogens.Antimicrob Agents Chemother, 1993,37 (9): 2033.
2Mcosker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother, 1994,33 ( Suppl A): 23.
3Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs, 2001,61(3): 353.
4Zhanel GG, Karlowsky JA, Harding GK, et al. A Canadian national surveillance study of urinary tract isolates from outpatients:comparison of the activities of trimethoprim - sulfamethoxazole,ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother, 2000, 44 (4): 1089.
5Burke JP, Riley DK. Nosocomial urinary tract infections. In:Mayhall CG. Hospital epidemiology and infection control. Philadelphia (PA): Lippincott, Williams & Wilkins, 1996: 139-53.
6Warren JW. Catheter- associated urinary tract infections. Infect Dis Clin North Am 1997,11: 609.
7Brumfitt W, Hamilton - Miller JMT. Efficacy and safety profile of long- term nitrofurantoin in urinary infections: 18 years' experience. J Antimicrob Chemother,1998, 42: 363.
8Stein GE. Comparison of single - dose fosfomycin and a 7 - day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther, 1999,21( 11 ): 1864.
9Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis ,1999,29:745.
10Tambyah PA, Halvorson KT, Maki DG. A prospective study of pathogenesis of catheter - associated urinary tract infections.Mayo Clin Proc, 1999,74: 131.
